Vertex Reports First-Quarter 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- S&P 500 volatile in choppy trading; Mideast deal, SpaceX debut in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Oil nears two-month lows on reports of imminent US-Iran peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Wall St set to gain on tech rebound, Middle East in focus
Vertex Pharma (VRTX) Tops Q1 EPS by 72c, Revenues Beat; Raises FY20 Revenues Guidance
April 29, 2020 4:04 PM EDTVertex Pharma (NASDAQ: VRTX) reported Q1 EPS of $2.56, $0.72 better than the analyst estimate of $1.84. Revenue for the quarter came in at $1.52 billion versus the consensus estimate of $1.29 billion.
"The COVID-19 pandemic has presented unprecedented challenges to societies, communities and businesses around the world, and while these global challenges will... More
